Bidany-Mizrahi T, Maroun K, Mancini M, Hidmi O, Ansari I, Monin J, Keidar Haran T, Maly A, Melino G, Candi E, Aqeilan RI. WWOX maintains epidermal identity and suppresses EMT to prevent aggressive cutaneous squamous cell carcinoma. Proc Natl Acad Sci U S A. 2026 Apr 21; 123(16):e2534844123.

Federico A, Schmitt-Hoffner F, Fonseca A, Geisemeyer N, Bruckner K, Mauermann M, Sill M, Stichel D, Sturm D, Schüller U, Tauziede-Espariat A, Varlet P, Capper D, Abdullaev Z, Schrimpf D, Selt F, Williamson L, Donson AM, Antonelli M, Miele E, Snuderl M, Brandner S, Lastowska M, van der Lugt J, Bunt J, Kramm C, Kolenova A, Raghunathan A, Wilson Y, Weintraub L, Hansford JR, Spiegl-Kreinecker S, Aistleitner B, Baroni L, Zapotocky M, Ramaswamy V, Korshunov A, Jones B, Kjaersgaard M, Kranendonk ME, Haberler C, Packer RJ, Jäger N, von Deimling A, Sahm F, Koster J, Aldape K, Pfister SM, von Hoff K, Gojo J, Kool M. Molecular and clinical stratification of astroblastomas: Three distinct fusion-defined groups informing risk-adapted treatment strategies. Neuro Oncol. 2026 Apr 01; 28(4):1005-1019.

Xu H, Kapur P, Christie A, Nielsen AW, Perny A, Brandenburg O, Small C, Miyata J, Zhong H, Roberts C, Elias R, Tcheuyap V, Duarte C, van Bokhoven A, Panian J, Li H, Collier KA, Zynger D, Meza L, Beuselinck B, Agarwal N, Mortazavi A, Pal S, McKay R, Lam ET, Rajaram S, Brugarolas J. Determinants of pancreatic tropism in metastatic renal cell carcinoma. JCI Insight. 2026 Mar 09; 11(5).

Selvam K, Lu S, Messmer C, Pang Y, Biswas S, Khalil M, Zhang P, Tulaiha R, Zhou MM, Kitamura T, Lauberth SM, Blanco MA, Yang FC, Affar EB, Zhao Z, Zeng L, Wang L, Kutateladze TG. Recruitment of BRD4 to the ASXL1 genomic targets depends on the extra-terminal domain of BRD4. Nat Commun. 2026 Feb 17; 17(1).

Bai X, Zhang J, Wang S, Huang K, Pan Z, Liang A, Wu W, Yu Z, Chen Y, Tong Y, Dai S, Chen Z. Novel intermolecular zinc fingers and redox-driven conformational changes dictate tumor suppressor ZMYND11's role in cooperative recognition of diverse targets. Nucleic Acids Res. 2026 Jan 22; 54(3).

Campwala I, Schienda J, Murphy AJ, Hashimi B, Perry T, Cost N, Kamihara J, Mullen EA, Santiago T, Malek MM. Wilms Tumor in Children With AMER1/WTX Germline Pathogenic Variants: A Multicenter Case Series. Pediatr Blood Cancer. 2025 Aug; 72(8):e31798.

Fleming JL, Pugh SL, Chang SM, McElroy JP, Becker AP, Aldape KD, Shih HA, Ashby LS, Hunter GK, Bahary JP, Schultz CJ, Kavanagh BD, Puduvalli VK, Robins HI, Werner-Wasik M, Mehta M, Chakravarti A. Comprehensive Molecular Analysis in NRG Oncology/RTOG 9813: A Phase 3 Study of Radiation and Temozolomide Versus Radiation and BCNU/CCNU in Anaplastic Astrocytoma. Int J Radiat Oncol Biol Phys. 2025 Sep 01; 123(1):84-92.

Flynn A, Pattison AD, Balachander S, Boehm E, Bowen B, Dwight T, Rossello FJ, Hofmann O, Martelotto L, Zethoven M, Kirschner LS, Else T, Fishbein L, Gill AJ, Tischler AS, Giordano T, Prodanov T, Noble JR, Reddel RR, Trainer AH, Ghayee HK, Bourdeau I, Elston M, Ishak D, Ngeow Yuen Yie J, Hicks RJ, Crona J, Åkerström T, Stålberg P, Dahia P, Grimmond S, Clifton-Bligh R, Pacak K, Tothill RW. Multi-omic analysis of SDHB-deficient pheochromocytomas and paragangliomas identifies metastasis and treatment-related molecular profiles. Nat Commun. 2025 Mar 17; 16(1):2632.

Biswas S, Lee JE, Xie G, Masclef L, Ren Z, Côté J, Affar EB, Ge K, Kutateladze TG. Colorectal cancer hot spot mutations attenuate the ASXL-MLL4 interaction. J Biol Chem. 2025 03; 301(3):108333.

Skoulidis F, Araujo HA, Do MT, Qian Y, Sun X, Galan-Cobo A, Le JT, Montesion M, Palmer R, Jahchan N, Juan JM, Min C, Yu Y, Pan X, Arbour KC, Vokes N, Schmidt ST, Molkentine D, Owen DH, Memmott R, Patil PD, Marmarelis ME, Awad MM, Murray JC, Hellyer JA, Gainor JF, Dimou A, Bestvina CM, Shu CA, Riess JW, Blakely CM, Pecot CV, Mezquita L, Tabbó F, Scheffler M, Digumarthy S, Mooradian MJ, Sacher AG, Lau SCM, Saltos AN, Rotow J, Johnson RP, Liu C, Stewart T, Goldberg SB, Killam J, Walther Z, Schalper K, Davies KD, Woodcock MG, Anagnostou V, Marrone KA, Forde PM, Ricciuti B, Venkatraman D, Van Allen EM, Cummings AL, Goldman JW, Shaish H, Kier M, Katz S, Aggarwal C, Ni Y, Azok JT, Segal J, Ritterhouse L, Neal JW, Lacroix L, Elamin YY, Negrao MV, Le X, Lam VK, Lewis WE, Kemp HN, Carter B, Roth JA, Swisher S, Lee R, Zhou T, Poteete A, Kong Y, Takehara T, Paula AG, Parra Cuentas ER, Behrens C, Wistuba II, Zhang J, Blumenschein GR, Gay C, Byers LA, Gibbons DL, Tsao A, Lee JJ, Bivona TG, Camidge DR, Gray JE, Leighl NB, Levy B, Brahmer JR, Garassino MC, Gandara DR, Garon EB, Rizvi NA, Scagliotti GV, Wolf J, Planchard D, Besse B, Herbst RS, Wakelee HA, Pennell NA, Shaw AT, Jänne PA, Carbone DP, Hellmann MD, Rudin CM, Albacker L, Mann H, Zhu Z, Lai Z, Stewart R, Peters S, Johnson ML, Wong KK, Huang A, Winslow MM, Rosen MJ, Winters IP, Papadimitrakopoulou VA, Cascone T, Jewsbury P, Heymach JV. CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors. Nature. 2024 11; 635(8038):462-471.